| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01646762 Details | 2017-10-16 Interventional | 2 | 13 | Albumin-Bound P… Paclitaxel Multiple Myelom… Neoplasms, Plas… Refractory Plas… | Did not pass the Stage 1 interim analysis. - | |||
| NCT02049385 Details | 2017-10-13 Interventional | 1/2 | 10 | Diazoxide Depression Depressive Diso… | Severe side effects & lack of target engagement As only 1 participant completed both treatment arms, no formal statistical analysis of the primary outcome (MADRS) possible. Study halted due to severe side effects & lack of target (KATP channel) engagement measured by insulin sensitivity index. | |||
| NCT03190798 Details | 2017-10-12 Interventional | 4 | 0 | Canagliflozin Cardiovascular … Diabetes Mellit… Diabetes Mellit… Type2 Diabetes … | Study has been withdrawn from IRB review pending IND revision - | |||
| NCT02342600 Details | 2017-10-12 Interventional | 2 | 0 | Trametinib Gastrointestina… | Supporting company withdrew interest - | |||
| NCT03277755 Details | 2017-10-11 Interventional | 1 | 0 | Adafosbuvir Hepatic Impairm… | Development program of JNJ-4178 was discontinued. - | |||
| NCT02068157 Details | 2017-10-11 Interventional | 2 | 3 | Dihematoporphyr… Trioxsalen Carcinoma Carcinoma, Squa… Carcinoma, Verr… Recurrence Squamous Cell C… Recurrent Laryn… Recurrent Laryn… Recurrent Lip a… Recurrent Metas… Recurrent Oral … Recurrent Oroph… Tongue Carcinom… | Study no longer has an active IDE - | |||
| NCT00725946 Details | 2017-10-11 Interventional | 1 | 7 | Cadexomer iodin… Iodine Breast Neoplasm… Breast Cancer Breast Cancer E… Breast Cancer M… | - - | |||
| NCT02032654 2013-002106-31 Details | 2017-10-10 Interventional | 4 | 151 | Floxacillin Cellulitis Erysipelas | Budget exceeded - | |||
| NCT02774512 Details | 2017-10-06 Interventional | 1 | 0 | Nilotinib Colonic Neoplas… Colon Cancer | none participant has been enrolled and recruited during the first year after competent autority
autorisation. - | |||
| NCT02534129 Details | 2017-10-06 Interventional | 1/2 | 13 | Petrolatum Dermatitis Radiodermatitis | Insufficient dermatitis was seen in the controls to allow any determination of protection by
Difinsa53 This trial was terminated early, based on minimal radiation dermatitis (scores of 0-1 only in most fields evaluated) that precluded any meaningful analysis of any differing effect in the two treatment arms. | |||
| NCT01768988 Details | 2017-10-06 Interventional | 4 | 20 | Pregabalin Cancer Pain Pancreatic Neop… Visceral Pain Pancreatic Canc… | Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to
change the PI. - | |||
| NCT01688336 Details | 2017-10-06 Interventional | 2 | 9 | Folfirinox Irinotecan Leucovorin Oxaliplatin Pancreatic Neop… Pancreatic Canc… | Results unlikely to impact treatment patterns. Time to complete not justified. - | |||
| NCT01511107 Details | 2017-10-06 Interventional | 2 | 520 | Amoxicillin Amoxicillin-Pot… Clavulanic Acid Clavulanic Acid… Otitis Otitis Media Acute Otitis Me… | The primary objective of the study was met. - | |||
| NCT00001827 NCT00019903 Details | 2017-10-06 Interventional | 2 | 21 | Aldesleukin Freund's Adjuva… Sargramostim Ovarian Neoplas… Ovarian Neoplas… | - - | |||
| NCT01310803 Details | 2017-10-05 Interventional | 3 | 1 | Valrubicin Carcinoma Carcinoma in Si… Carcinoma, Tran… Non-Muscle Inva… Non-muscle Inva… Transitional Ce… | - This study was terminated early. Only one subject was enrolled. No study results were generated. | |||
| NCT03002454 Details | 2017-10-03 Interventional | 3 | 4 | Sodium Pertechn… Technetium Tc 9… Bone Neoplasms Cancer of Bone | Altered biodistribution in investigational images versus standard images. Early termination. Despite a relatively comprehensive review of the first four subject's bone imaging scans a cause of an observed altered biodistribution is not apparent. As such study recruitment will be terminated. | |||
| NCT01399593 2010-019630-28 Details | 2017-10-03 Interventional | 2 | 102 | Eculizumab Antibody Mediat… | Did not achieve statistical significance for primary endpoint Data interpretation confounded by open-label study with potential reporting bias, unequal exposure to randomized prevention therapy between groups, some patients in SOC arm received eculizumab for treatment of AMR, all patients immunosuppressed. | |||
| NCT00994253 Details | 2017-10-02 Interventional | 4 | 0 | Aliskiren Hydrochlorothia… Diabetes Mellit… Hypertension Diabetes Type 2 | Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB. - | |||
| NCT02113735 Details | 2017-09-27 Interventional | 2 | 0 | Adrenocorticotr… Acute Lung Inju… Respiratory Dis… Respiratory Dis… Syndrome Acute Respirato… | A company decision was made not to proceed with the study. - | |||
| NCT01436305 Details | 2017-09-27 Interventional | 2 | [1 Refs] | 19 | Abatacept Alemtuzumab Basiliximab Methylprednisol… Mycophenolic Ac… Tacrolimus Kidney Transpla… Renal Transplan… | Secondary to safety concerns plus change in Campath® (alemtuzumab) availability. Enrollment of 210 participants was planned, but study was stopped after 19 participants enrolled due to safety concerns and change in alemtuzumab availability. Enrolled participants continued follow-up after enrollment ended. |